Subscribe
shutterstock_1548704417_nitpicker-1
26 January 2023Big PharmaLiz Hockley

BMS sues AstraZeneca for infringing cancer treatment drug

US pharma giant says competitor’s drug Imjudo violates two patents | BMS’ blockbuster was first to use checkpoint inhibitors, says complaint.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
BMS says Hengrui’s Abraxane infringes
13 May 2022   A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane infringes a patent.
Generics
Gilead, BMS, Janssen facing HIV generic antitrust suit
16 December 2021   Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.
Big Pharma
Exelixis takes Cipla to court over generic cancer drug
21 March 2023   Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Generics
BMS says Hengrui’s Abraxane infringes
13 May 2022   A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane infringes a patent.
Generics
Gilead, BMS, Janssen facing HIV generic antitrust suit
16 December 2021   Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.
Big Pharma
Exelixis takes Cipla to court over generic cancer drug
21 March 2023   Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.

More on this story

Generics
BMS says Hengrui’s Abraxane infringes
13 May 2022   A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane infringes a patent.
Generics
Gilead, BMS, Janssen facing HIV generic antitrust suit
16 December 2021   Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.
Big Pharma
Exelixis takes Cipla to court over generic cancer drug
21 March 2023   Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?